House Dust Mite extract (Acarizax®) is indicated in adult patients (18-65 years) with HDM allergic asthma not well controlled by inhaled corticosteroids (ICS) and associated with mild to severe house dust mite allergic rhinitis. Diagnosis should be confirmed by clinical history and a positive test of HDM sensitisation (skin prick test and/or specific IgE).
|NCPE Assessment Process||Complete|
|Rapid review commissioned||12/03/2020|
|Rapid review completed||30/04/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of HDM extract (Acarizax ®) for allergic asthma compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||07/05/2020|
|Pre-submission consultation with Applicant||08/06/2020|
|Current status||Awaiting Applicant Submission|
The company has not submitted a HTA dossier to the NCPE; therefore the cost-effectiveness of the technology could not be proven.